Antineoplastic Agents Market

New anti-tumor targets and corresponding new anti-tumor agents or means are: targeting cell signal transduction molecules, including protein tyrosine kinase inhibitors, farnesyltransferase (FTase) inhibitors, MAPK signaling pathway inhibitors, and cell cycle regulators.Targeting neovascularization: neovascularization inhibitors;To reduce the detachment, adhesion and basement membrane degradation of cancer cells: anti-metastasis drugs;Targeting telomerase: telomerase inhibitor;Drug resistance to tumor cells: drug resistance reversal agent;Promoting the mature differentiation of malignant cells: differentiation inducers;Specific killing of cancer cells :(antibody or toxin) directed therapy;Enhance the efficacy of radiotherapy and chemotherapy: tumor treatment sensitizers;Enhance or regulate collective immune function: biological response modulator;For oncogenes and tumor suppressor genes: gene therapy - introduction of wild-type tumor suppressor genes, suicide genes, anti-drug resistance genes and antisense oligonucleotides, tumor genetic engineering tumor bacteria.

Antineoplastic Agents Market contains market size and forecasts of Antineoplastic Agents in Global, including the following market information:

Global Antineoplastic Agents Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Antineoplastic Agents market was valued at 4432.3 million in 2021 and is projected to reach US$ 5064.7 million by 2028, at a CAGR of 1.9% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

by Treatment Means Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Antineoplastic Agents include BMS, MSD, Johnson & Johnson, Pfizer, AstraZeneca, Novartis, Sanofi, Celgene and Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Antineoplastic Agents companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Antineoplastic Agents Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Antineoplastic Agents Market Segment Percentages, by Type, 2021 (%)

by Treatment Means

Chemotherapy

Targeted Therapy

Immunotherapy

Hormonal Therapy (Biologic Therapy)

Others

by Dosage Form

Injection

Tablets

Capsule

Suppository

Granules

Implant

??

by Nature of the Drug

Pharmaceutical Chemicals

Biological Medicine

Natural Product

Global Antineoplastic Agents Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Antineoplastic Agents Market Segment Percentages, by Application, 2021 (%)

Plant Medicine

Hormone

Platinum Compounds

Metabolism Of Drug Resistance

Targeting Small Molecules

Drugs For Cancer

Antibiotic

Alkylating Agent

Chemoradiotherapy Protectant

Other

Global Antineoplastic Agents Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Antineoplastic Agents Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Antineoplastic Agents revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Antineoplastic Agents revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

BMS

MSD

Johnson & Johnson

Pfizer

AstraZeneca

Novartis

Sanofi

Celgene

Roche

Lilly

Bayer

Abraxis

Gilead

Wto-Day Order Pharmaceutical

Sinopharm

Shandong Lvye Pharmaceutical

CTTQ

Jiangsu Hengrui Pharmaceutical

Qilu Pharmaceutical

Baekdu Mountain Pharmaceutical

Baida Pharmaceutical

Jiangsu Haosen Pharmaceutical Group

Hainan Chang'an International Pharmaceutical

Zhejiang Kanglaite Pharmaceutical

Shandong New Era Pharmaceutical

Liaoning Novino Pharmaceutical

Maanshan Fengyuan Pharmaceutical

Meiluo Pharmaceutical

Shandong Luoxin Pharmaceutical Group

Zhejiang Yatai Pharmaceutical

Tesaro (GSK)

Eisai

Biogen Idec

Teva

AbbVie